Regulus Therapeutics Inc.
NASDAQ:RGLS
Overview | Financials
| Company Name | Regulus Therapeutics Inc. |
| Symbol | RGLS |
| Currency | USD |
| Price | 8.16 |
| Market Cap | 564,950,256 |
| Dividend Yield | 0% |
| 52-week-range | 0.83 - 8.345 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Joseph P. Hagan M.B.A. |
| Website | https://www.regulusrx.com |
An error occurred while fetching data.
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD




